Companies: 10,795·Total market cap: $144.5T
Accelerate Diagnostics, Inc.

Accelerate Diagnostics, Inc.

AXDXNASDAQHealthcare
$0.03
+$0.00(+0.00%)
Market Cap$859918
P/E Ratio
52W High$2.09
52W Low$0.01
Overview

Accelerate Diagnostics, Inc.(AXDX)股价预测与分析师目标价

华尔街共识、12 个月目标价、模型推演与 EPS/营收预期 — 来自分析师数据与历史行情。

axdx · 股价预测 · 4 位分析师(近3月)· FMP · 更新于 2026年2月3日

分析师评级与共识

基于过去 3 个月内 4 位华尔街分析师

SellBuy

Hold

4 位分析师

共识

评级分布

Strong Buy
0
Buy
1
Hold
2
Sell
1
Strong Sell
0
合计: 4 · 买入占比: 25.0%

12 个月目标价

High

$0.00

Consensus

$0.00

+0.0% upside

Low

$0.00

Median: $0 · Last Close: $0.01

Accelerate Diagnostics, Inc.(AXDX)的分析师共识为 Hold,基于过去 3 个月内 4 位华尔街分析师的评级。AXDX 的 12 个月平均目标价为 $0.00,相对当前价 $0.01 代表 +0.0% 的潜在上行空间。

短期股价预测

算法生成 · 每日更新

DatePredicted PriceChange
2026-06-10$0.010.00%

1-day model range: $0.01–$0.01. Peak: $0.01 (+0.00%).

长期股价预测

⚠️ 在满 252 个交易日历史(IPO/上市时间较短)前不展示长期预测;短期标签页仍可能显示模型输出。

基于技术分析的股价预测

14 项技术面信号(SMA×6 + EMA×6 + RSI + MACD)· EEAT 方法论透明

Market Sentiment

NEUTRAL

Based on 14 technical indicators

0%86%14%
0Buy
12Neutral
2Sell
RSI (14)50.0Neutral
MACDNEUTRAL

Refreshes daily from EOD close

Moving Averages · AXDX · Jun 9, 2026

Simple Moving Average (SMA)
MA 5$0.01SELL
MA 10$0.00NEUTRAL
MA 20$0.00NEUTRAL
MA 50$0.00NEUTRAL
MA 100$0.00NEUTRAL
MA 200$0.00NEUTRAL
Current $AXDX · Price above MA = BUY signal
Exponential Moving Average (EMA)
EMA 5$0.01SELL
EMA 10$0.00NEUTRAL
EMA 20$0.00NEUTRAL
EMA 50$0.00NEUTRAL
EMA 100$0.00NEUTRAL
EMA 200$0.00NEUTRAL
Current $AXDX · Price above MA = BUY signal
How we calculate: Technical sentiment is derived from 14 indicators — SMA(5,10,20,50,100,200), EMA(5,10,20,50,100,200), RSI(14), and MACD(12,26,9) — calculated from historical EOD price data. BUY = current price above MA; SELL = below. 14 TA signals + historical EOD price data · Updated daily. Independent of analyst consensus data. Not investment advice.

最新分析师评级与调整

Filter:
Craig-Hallum2024-04-01
Maintains
HoldHold
Craig-Hallum2022-03-09
Downgrade ↓
BuyHold
Piper Sandler2020-08-10
Maintains
OverweightOverweight
JP Morgan2019-09-27
Downgrade ↓
NeutralUnderweight
JP Morgan2018-11-07
Downgrade ↓
OverweightNeutral
BTIG Research2017-12-19
Downgrade ↓
BuyNeutral
BTIG Research2017-12-13
Downgrade ↓
BuyNeutral
JP Morgan2016-08-09
Maintains
OverweightOverweight
BTIG Research2015-08-25
Upgrade ↑
NeutralBuy

Wall Street analysts have recently issued updated ratings on Accelerate Diagnostics, Inc. (AXDX) stock. Of the recent 9 rating actions, 1 were upgrades and 5 were downgrades. 4 analysts currently cover AXDX.

分析师推荐趋势

Buy ratings00
Hold ratings211
Sell ratings00

AXDX analyst recommendation trends show stable buy-side sentiment over the past 6 months. Buy rating actions changed from 0 to 0 per month.

财务预测:EPS 与营收一致预期

Revenue This Year

$13M

↑ 6.4% YoY

Revenue Next Year

$12M

↓ 1.6% YoY

EPS This Year

$-7.78

EPS Next Year

$-4.83

↓ 38.0% YoY

EPS ForecastReported vs Estimated

Reported EPSHistorical estimateAnalyst forecast (future)

Analysts forecast AXDX EPS of $-7.78 for the current fiscal year, based on estimates from 1 analysts. The AXDX revenue forecast is $13M for the current year. These are analyst consensus estimates via FMP / S&P Global.

关于预测与目标价

AXDX 股价预测由两类独立数据源支撑:来自 4 位华尔街分析师(S&P Global / FMP)的共识评级,以及基于历史日终价计算的技术分析。AXDX 的共识目标价为 $0.00(+0.0% 上行空间),分析师共识为 Hold。

AXDX 的短期预测(明日)为 $0.01(+0.00%)。

Accelerate Diagnostics, Inc. 在 NASDAQ 上市,代码 AXDX。AXDX 在 2027 年的整体展望偏中性/分化,在覆盖分析师中约 25% 对应 Hold 共识。

常见问题答案综合分析师目标价、一致预期及页面展示的模型结果。

常见问题

AXDX 预测 · 8 个问题

根据 4 位华尔街分析师,AXDX 的 12 个月平均目标价为 $0.00,最高 $0.00、最低 $0.00。若有图表,中位目标价可在上方查看。相对当前价 $0.01,隐含约 +0.0% 的上行空间。

AXDX 目标价AXDX 分析师目标价AXDX 12个月目标价目标价 AXDX

· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)

⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.